Sacrococcygeal chordoma (Literature review, clinical case)
Abstract
Sacrococcygeal chordomas are relatively rare, locally invasive, malignant neoplasms. The prognosis for patients with chordoma of the sacrum is reported to be poor, the value of adjuvant treatment is uncertain, and resection remains the primary mode of treatment, even though most of the patients might subsequently have significant complications. Neurologic impairment and disability are the most common complications. The severity and extent of neurological impairment depends upon the level of tumor involvement. Chordomas are difficult to excise completely, but recent improvements in imaging and surgical techniques have allowed surgeons to perform more frequently en-bloc sacral resections with wide surgical margins. In this paper we review the clinical presentation and discuss the current treatment techniques and outcomes.
About the Authors
V. V. Teplyakov
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
S. V. Goncharov
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. P. Bliznyukov
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. A. Horonenko
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
N. A. Bolihova
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
U. S. Stanoevich
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
D. V. Barishnikova
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. A. Shaposhnikov
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. V. Lazukin
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. O. Akhov
Russian Scientific Center of Radiography and Radiology Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
References
1. Алиев МД. Злокачественные опухоли костей. М.: Издательская группа РОНЦ. 2008:408.
2. Коновалов АН, Сидоркин ДВ, Шкарубо АН, Усачёв ДЮ, Махмудов УБ. Хордомы основания черепа и краниовертебрального перехода М., 2014:3-5.
3. Мусаев ЭР. Опухоли крестца: дис. канд. мед. наук. М., 1999:102.
4. Тепляков ВВ, Чиссов ВИ, Франк ГА. Хирургическое лечение пациентов с опухолями тазового кольца. Российский онкологический журнал. М.: Издательство «Медицина». 2011;(3):15-21.
5. Тепляков ВВ. Реконструктивные операции при лечении пациентов со злокачественными опухолями тазового кольца. Саркомы костей, мягких тканей, опухоли кожи. М.: «Фармарус Принт Медиа». 2012;(3):16-27.
6. Bergh P, Kindblom LG, Gunterberg B, Remotti F, Ryd W, Meis-Kindblom J. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122-2134.
7. Boriani S, Chevalley F, Weinstein JN et al. Chordoma of the spine above the sacrum. Treatment and outcome in 21 cases. Spine. 1996;21:1569-1577.
8. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19:367-370.
9. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007;12(11):1344-1350.
10. Chugh R, Dunn R, Zalupski MM et al. Phase II study of 9-nitrocamptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005;23:3597-3604.
11. George S, Merriam P, Maki RG et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-3160.
12. Gunterberg B, Norlen L, Stener B, Sundin T Neurourologic evaluation after resection of the sacrum. Invest Urol. 1975;13:183-188.
13. Hof H, Welzel T Debus J. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma. Onkologie. 2006;29:572-574.
14. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TWR. A review of the surgical management of sacral chordoma The Royal National Orthopaedic Hospital, Stanmore, UK Accepted 9 April 2014.
15. Negri T, Casieri P, Miselli F et al. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient. Br J Cancer. 2007;96:180-181.
16. Noël G, Feuvret L, Calugaru V et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformai technique combining photon and proton beams. Acta Oncol. 2005;44:700-708.
17. Osaka S, Kodoh O, Sugita H, Osaka E, Yoshida X Ryu J. Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol. 2006;132:213-218.
18. Stacchiotti S, Marrari A, Tamborini E et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 2009;20:1886-1894.
Review
For citations:
Teplyakov V.V., Goncharov S.V., Bliznyukov O.P., Horonenko N.A., Bolihova N.A., Stanoevich U.S., Barishnikova D.V., Shaposhnikov A.A., Lazukin A.V., Akhov A.O. Sacrococcygeal chordoma (Literature review, clinical case). Bone and soft tissue sarcomas, tumors of the skin. 2018;10(2):28-42. (In Russ.)
Views:
173
Email this article 
